Lilly’s Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis

December 1, 2017

Responsive image

INDIANAPOLIS, Dec. 1, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).1 Taltz was first approved by…

Category: Precious Metals